Literature DB >> 10796394

Calcium and vitamin D for corticosteroid-induced osteoporosis.

J Homik1, M E Suarez-Almazor, B Shea, A Cranney, G Wells, P Tugwell.   

Abstract

OBJECTIVES: To assess the effects of calcium and vitamin D compared to calcium alone or placebo in the prevention of bone loss in patients taking systemic corticosteroids. SEARCH STRATEGY: We searched the Cochrane Musculoskeletal trials register, Cochrane Controlled Trials Register, EMBASE and Medline up to 1996. We also conducted a hand search of abstracts from various scientific meetings and reference lists of selected trials. SELECTION CRITERIA: All randomized trials comparing calcium and vitamin D to calcium alone or placebo in patients taking systemic corticosteroids. DATA COLLECTION AND ANALYSIS: Data was abstracted from trials by two investigators. Methodological quality was assessed in a similar manner. Analysis was performed using fixed effects models. MAIN
RESULTS: Five trials were included, with 274 patients. The analysis was performed at two years after starting calcium and vitamin D. There was a significant weighted mean difference (WMD) between treatment and control groups in lumbar (WMD 2.6 (95% CI 0.7, 4.5), and radial bone mineral density (WMD 2.5 (95% CI 0.6, 4.4). The other outcome measures (femoral neck bone mass, fracture incidence, biochemical markers of bone resorption) were not significantly different. REVIEWER'S
CONCLUSIONS: This meta-analysis demonstrated a clinically and statistically significant prevention of bone loss at the lumbar spine and forearm with vitamin D and calcium in corticosteroid treated patients. Because of low toxicity and cost all patients being started on corticosteroids should receive prophylactic therapy with calcium and vitamin D.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10796394      PMCID: PMC7046131          DOI: 10.1002/14651858.CD000952

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  10 in total

1.  Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Authors:  A R Jadad; R A Moore; D Carroll; C Jenkinson; D J Reynolds; D J Gavaghan; H J McQuay
Journal:  Control Clin Trials       Date:  1996-02

2.  Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial.

Authors:  L M Buckley; E S Leib; K S Cartularo; P M Vacek; S M Cooper
Journal:  Ann Intern Med       Date:  1996-12-15       Impact factor: 25.391

Review 3.  Identifying relevant studies for systematic reviews.

Authors:  K Dickersin; R Scherer; C Lefebvre
Journal:  BMJ       Date:  1994-11-12

4.  Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study.

Authors:  J J Braun; D H Birkenhäger-Frenkel; A H Rietveld; J R Juttmann; T J Visser; J C Birkenhäger
Journal:  Clin Endocrinol (Oxf)       Date:  1983-08       Impact factor: 3.478

5.  Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup.

Authors:  J D Adachi; W G Bensen; F Bianchi; A Cividino; S Pillersdorf; R J Sebaldt; P Tugwell; M Gordon; M Steele; C Webber; C H Goldsmith
Journal:  J Rheumatol       Date:  1996-06       Impact factor: 4.666

6.  Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration.

Authors:  T J Hahn; L R Halstead; S L Teitelbaum; B H Hahn
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

7.  Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.

Authors:  P Sambrook; J Birmingham; P Kelly; S Kempler; T Nguyen; N Pocock; J Eisman
Journal:  N Engl J Med       Date:  1993-06-17       Impact factor: 91.245

8.  Prevention of glucocorticoid-induced osteopenia: effect of oral 25-hydroxyvitamin D and calcium.

Authors:  O Di Munno; F Beghe; P Favini; P Di Giuseppe; A Pontrandolfo; G Occhipinti; G Pasero
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

9.  Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation.

Authors:  H Vogelsang; P Ferenci; H Resch; A Kiss; A Gangl
Journal:  Eur J Gastroenterol Hepatol       Date:  1995-07       Impact factor: 2.566

10.  Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases.

Authors:  T R Dykman; K M Haralson; O S Gluck; W A Murphy; S L Teitelbaum; T J Hahn; B H Hahn
Journal:  Arthritis Rheum       Date:  1984-12
  10 in total
  43 in total

Review 1.  Inflammatory bowel disease.

Authors:  R M Beattie; N M Croft; J M Fell; N A Afzal; R B Heuschkel
Journal:  Arch Dis Child       Date:  2006-05       Impact factor: 3.791

Review 2.  Standards of medical treatment and nutrition in Crohn's disease.

Authors:  Britta Siegmund; Martin Zeitz
Journal:  Langenbecks Arch Surg       Date:  2004-09-23       Impact factor: 3.445

Review 3.  Musculoskeletal pain associated with corticosteroid therapy in cancer.

Authors:  Deborah A Frieze
Journal:  Curr Pain Headache Rep       Date:  2010-08

4.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

Review 5.  Review of new guidelines for the management of glucocorticoid induced osteoporosis.

Authors:  Swamy R Venuturupalli; Wendy Sacks
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

Review 6.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.

Authors:  Laurence Fardet; Abdulrhaman Kassar; Jean Cabane; Antoine Flahault
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

7.  Glucocorticoid-induced osteoporosis: treatment update and review.

Authors:  Lisa-Ann Fraser; Jonathan D Adachi
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

Review 8.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

9.  Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study.

Authors:  G Haugeberg; B Griffiths; K B Sokoll; P Emery
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

Review 10.  Prevention and treatment of corticosteroid-induced osteoporosis.

Authors:  Jun Iwamoto; Tsuyoshi Takeda; Yoshihiro Sato
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.